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Abstract
Multiple genome-wide association studies (GWAS) have been performed in HIV-1 infected individuals, identifying common
genetic influences on viral control and disease course. Similarly, common genetic correlates of acquisition of HIV-1 after exposure
have been interrogated using GWAS, although in generally small samples. Under the auspices of the International Collaboration
for the Genomics of HIV, we have combined the genome-wide single nucleotide polymorphism (SNP) data collected by 25
cohorts, studies, or institutions on HIV-1 infected individuals and compared them to carefully matched population-level data sets
(a list of all collaborators appears in Note S1 in Text S1). After imputation using the 1,000 Genomes Project reference panel, we
tested approximately 8 million common DNA variants (SNPs and indels) for association with HIV-1 acquisition in 6,334 infected
patients and 7,247 population samples of European ancestry. Initial association testing identified the SNP rs4418214, the C allele
of which is known to tag the HLA-B*57:01 and B*27:05 alleles, as genome-wide significant (p=3.6610211). However, restricting
analysis to individuals with a known date of seroconversion suggested that this association was due to the frailty bias in studies of
lethal diseases. Further analyses including testing recessive genetic models, testing for bulk effects of non-genome-wide
significant variants, stratifying by sexual or parenteral transmission risk and testing previously reported associations showed no
evidence for genetic influence on HIV-1 acquisition (with the exception of CCR5D32 homozygosity). Thus, these data suggest that
genetic influences on HIV acquisition are either rare or have smaller effects than can be detected by this sample size.
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Introduction
Variation in infection susceptibility and severity is a hallmark of
infectious disease biology. This natural variation can be attributed
to a variety of host, pathogen and environmental factors, including
host genetics. Several genome-wide association studies (GWAS) of
HIV-1 outcomes have been performed primarily to assess the
impact of human genetic variation on plasma viral load and/or
disease progression [1,2,3,4,5,6,7,8,9,10,11]. These studies have
confirmed the key role of major histocompatibility complex
(MHC) polymorphisms in HIV-1 control, with a minor impact
of variants in the CCR5 gene region.
A smaller number of GWAS have also investigated host genetic
influences on HIV-1 acquisition using samples of individuals with
known or presumed exposure to an HIV-1 infected source
[12,13,14,15,16]. With the exception of CCR5D32 homozygosity
(known to explain a proportion of HIV-1 resistance in Europeans
[17]), no reproducible associations with increased or reduced
HIV-1 acquisition have been observed. Additionally, several
variants reported to influence HIV-1 acquisition by candidate
gene studies have either failed to be replicated or lacked sufficient
investigation as to be considered confirmed.
We here describe a large study of human genetic determinants
of HIV-1 acquisition, performed under the auspices of the
International Collaboration for the Genomics of HIV, a collab-
orative research effort bringing together the HIV-1 host genetics
community. By collecting for the first time all available genome-
wide single nucleotide polymorphism (SNP) data on HIV-1
infected individuals and comparing them with population-level
control data sets we sought to uncover common genetic markers
that influence HIV-1 acquisition.
Results
Association testing and meta-analysis
Genome-wide genotype data were collected from 25 cohort
studies and clinical centers (listed at the end of the paper and in
Note S1 in Text S1). We obtained a data set of 11,860 HIV-1
infected individuals genotyped at multiple centers using several
platforms (Table S1 in Text S1). The present analysis focused on
the subset of these individuals that are of European ancestry as
assessed by principal components (PCs) analysis (see methods).
For two of the genotyping centers, matched HIV-1 uninfected
controls were available. For the remaining samples, large
population-level control data sets were accessed from the
Illumina Genotype Control Database (www.illumina.com) and
the Myocardial Infarction Genetics (MIGen) Consortium
(genotyped using the Affymetrix 6.0 platform) [18]. Sample-
level quality control and case-control matching (Figure S1 in
Text S1) resulted in six non-overlapping data sets including
6,334 HIV-1 infected cases and 7,247 controls (Table S1 in Text
S1). After imputation, each variant was individually tested for
association with HIV-1 status by logistic regression including
PCs to correct for residual population structure, under additive
and recessive genetic models. Association results were then
combined across data sets.
Restricting to variants observed in all six data sets with .1%
frequency and a minimum imputation quality of 0.8 in at least 2
groups, approximately 86106 common variants (SNPs and indels)
were tested. The overall distribution of p-values was highly
consistent with the null hypothesis (l1000 = 1.01) suggesting that
the matching strategy was successful in minimizing inflation
(Figure 1a). We observed 11 SNPs with combined evidence for
association passing the genome-wide significance threshold
(p,561028, Figure 1b) under an additive genetic model. All
genome-wide significant SNPs were located in the MHC region,
centered on the class I HLA genes HLA-B/HLA-C (Figure 2a and
Table S2 in Text S1). The top SNP, rs4418214 (p= 3.6610211,
odds ratio (OR) for the C allele = 1.52) has previously been
associated with control of HIV-1 viral load [8], with the C allele
tagging the classical HLA-B alleles 57:01 and 27:05, both known to
associate with lower viral load and longer survival after infection.
Analysis assuming a recessive genetic model did not identify any
genome-wide significant associations (data not shown).
Exploration of top associations
Since variation in the HLA region is well known to impact rate
of HIV-1 disease progression and not acquisition, we sought to
better understand the observed associations at this locus. Due to
their shorter survival time, patients with rapid disease progression
are underrepresented in seroprevalent cohorts, while individuals
with prolonged disease-free survival times are more likely to be
included, leading to an enrichment of factors that protect against
disease progression in such populations. Additionally, some of the
cohorts accessed for this analysis specifically recruited long-term
non-progressors (LTNPs, Groups 2, 3 and 4). Inspection of the
effect estimates at the top SNP (rs4418214) per data set showed
that the majority of the association signal was driven by groups
specifically enriched for LTNPs (Figure 2b) suggesting a possible
frailty bias in the overall results.
To assess the potential contribution of frailty bias, we ran
association testing as previously but restricting the case popula-
GWAS of HIV-1 Acquisition in 13,500 Indivuals
PLOS Pathogens | www.plospathogens.org 2 July 2013 | Volume 9 | Issue 7 | e1003515
tion to 2,173 individuals with a known date of seroconversion
that were not enrolled in LTNP cohorts. Association testing in
this sample showed no variants passing the genome-wide
significance threshold. Additionally, rs4418214 dramatically
dropped in strength of association to p = 0.02, with all other
previously genome-wide significant SNPs suffering a similar loss
in association strength (Figure 2c and Table S2 in Text S1). In
order to address whether this loss of association signal could be
due to the reduced size of the case population rather than frailty
bias, we performed a sensitivity analysis where we tested for
association at rs4418214 restricting the HIV+ cases to 2,173
individuals randomly selected from the full case sample. We
repeated this procedure 1,000 times and compared the p-value
from the random case selection to that obtained when restricting
to seroconverters. Of these 1,000 tests, only one resulted in a loss
of association signal that was similar to what was observed when
restricting to seroconverters (Figure S2 in Text S1). This suggests
that the signal observed in the full acquisition analysis is most
likely due to frailty bias.
Polygenic analysis
Previous studies in large cohorts have shown that multiple
genetic variants with small effect sizes that contribute to complex
traits, but fall below the genome-wide significance threshold, can
be detected by examining the consistency of their combined effects
across studies [19]. We sought to test for evidence of such
polygenic inheritance in our study population. To do this (and to
avoid overfitting), we split our sample into a discovery set (Groups
1,2,4,5 and 6) and a test set (Group 3) and performed genome-
wide association testing and meta-analysis on the discovery set.
Based on these results, we generated sets of high-quality SNPs
(minor allele frequency .0.1, imputation accuracy .0.9) in
relative linkage equilibrium (r2,0.1, informed by p-value in the
discovery set, see methods) falling below various p-value thresholds
(PT). Scores were then generated for all individuals in Group 3 by
summing the weighted genotype dosage (using the log odds ratio
from the discovery set as weights) of all SNPs below a given PT.
Phenotype was then regressed on this score using logistic
regression including covariates. We assessed both the significance
of the score and the phenotypic variance explained (using
Nagelkerke’s pseudo-R2 [20]). We did not observe a significant
association between the calculated score and phenotype in the
discovery set at any PT (Figure 3). This further suggests that effects
of common variants on HIV-1 acquisition detectable by this study
design are negligible.
Analysis by transmission risk
Since different modes of HIV-1 transmission may be influenced
by different host factors, we further investigated if genetic variants
may contribute to enhanced HIV-1 acquisition within transmis-
sion risk sub-groups. We stratified the study population by
reported risk groups that were either primarily sexual (homosexual
and heterosexual, n = 3,311) or parenteral (injection drug use and
transfusion, n= 1,046). Association results in these sub-groups
were consistent with those observed in the full set with no genome-
wide significant signals detected (data not shown).
Association testing of variants previously reported to
influence HIV-1 acquisition
With the exception of CCR5D32 (addressed in the next section),
many variants reported to influence HIV-1 acquisition have
remained unconfirmed. We sought to assess the evidence for
Figure 1. Association results for approximately 8 million common DNA variants tested for an impact on HIV-1 acquisition. A)
Quantile-quantile plot of association results after meta-analysis across the six groups. For each variant tested, the observed 2log10 p-value is plotted
against the null expectation (dashed line). P-values lower than 561028 are truncated for visual effect. B) Manhattan plot of association results where
each variant is plotted by genomic position (x-axis) and 2log10 p-value (y-axis). Only variants in the MHC region on chromosome 6 have p-values
below genome-wide significance (p,561028 dashed line, large diamonds).
doi:10.1371/journal.ppat.1003515.g001
Author Summary
Comparing the frequency differences between common
DNA variants in disease-affected cases and in unaffected
controls has been successful in uncovering the genetic
component of multiple diseases. This approach is most
effective when large samples of cases and controls are
available. Here we combine information from multiple
studies of HIV infected patients, including more than 6,300
HIV+ individuals, with data from 7,200 general population
samples of European ancestry to test nearly 8 million
common DNA variants for an impact on HIV acquisition.
With this large sample we did not observe any single
common genetic variant that significantly associated with
HIV acquisition. We further tested 22 variants previously
identified by smaller studies as influencing HIV acquisition.
With the exception of a deletion polymorphism in the
CCR5 gene (CCR5D32) we found no convincing evidence to
support these previous associations. Taken together these
data suggest that genetic influences on HIV acquisition are
either rare or have smaller effects than can be detected by
this sample size.
GWAS of HIV-1 Acquisition in 13,500 Indivuals
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association of 22 variants previously reported to influence HIV-1
acquisition in this sample. All 22 of these variants could be
measured in this sample either through direct genotyping or
imputation. Of these, only one variant (rs1800872) showed
nominal significance (p,0.05, Table 1) although it did not survive
correction for the number of variants tested (p.2.561023). Thus,
none of the previously reported associations can be considered
confirmed in this large sample.
Power for variant detection
Parameters required for determining power for variant detec-
tion, specifically the trait prevalence and the level of enrichment of
enhanced HIV-1 acquisition, are difficult to estimate given this
study design. Thus, we sought to determine the extent to which we
could detect known genetic influences on HIV-1 acquisition in this
sample by assessing the depletion of CCR5D32 homozygosity in
the HIV-1 infected sample. Although this variant is not captured
by commercial arrays (and is not included in the 1,000 Genomes
Project reference panel), genotypes of the deletion were available
for a majority of the HIV-1 infected individuals (n = 4,854). As
expected, we observed very few D32/D32 homozygous individuals
in this sample (n = 4) and a large deviation from Hardy-Weinberg
equilibrium (Table S3 in Text S1).
To assess the association strength of this variant, we used a
subset of our sample with available CCR5D32 genotypes to build a
reference panel, which was then used for imputation of CCR5D32
in both cases and controls (see methods). Overall the imputation
accuracy was acceptable (average information score = 0.82) and
we observed good correspondence between typed and imputed
dosage (Figure S3 in Text S1). Using a recessive genetic model, we
observed a genome-wide significant association between CCR5D32
homozygosity and HIV-1 acquisition (p = 561029, OR=0.2). No
impact on HIV-1 acquisition was observed under any other
genetic model.
Figure 2. Common DNA variants within the MHC region that are associated with HIV-1 acquisition comparing 6,334 HIV-1 infected
patients to 7,247 population controls are driven by HIV-1 controllers and not maintained when restricting to patients with known
dates of seroconversion. A) Regional association plot of the locus containing genome-wide significant SNPs after meta-analysis. The signal of
association is centered on the HLA-B/HLA-C genes. The association result for the top SNP, rs4418214, is indicated by the purple diamond, with dark
blue indicating SNPs in high LD (r2.0.8), light blue indicating moderate LD (r2 between 0.2 and 0.8) and grey indicating low or no LD (r2,0.2) with
rs4418214. The dashed line indicates genome-wide significance (p,561028). The location of classical class I and class II HLA genes (green arrows) is
given as reference. B) Forest plot of effect estimates for the C allele at rs4418214 with 95% confidence intervals per group (box and whiskers) and
after meta-analysis (diamond). The majority of the association signal is contributed by Groups 3 and 4, which are enriched for HIV-1 controllers. C)
Regional association plot of the same variants as in A) but restricting analysis to include only individuals with a known date of seroconversion to limit
frailty bias.
doi:10.1371/journal.ppat.1003515.g002
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To address whether the association signal at CCR5D32 was
subject to the same frailty bias as the MHC SNPs, we next tested
for association between CCR5D32 and HIV acquisition restricting
only to the 2,173 HIV+ individuals with known dates of
seroconversion. Using these individuals, CCR5D32 remains
strongly associated (p= 161026 for the recessive model), suggest-
ing that the observed association statistic in the full set is not simply
due to frailty bias. This demonstrates that, despite an inability to
precisely estimate power, other variants of similar or somewhat
weaker effect could also have been detected in this sample.
Discussion
By assembling a large collaborative network of cohorts and
institutions involved in HIV-1 host genetic studies we sought to
test for common genetic polymorphisms that influence HIV-1
acquisition. Through this network, we were able to combine
genome-wide SNP data on over 6,300 HIV-1 infected patients of
European ancestry. In order to maximize power, we further
accessed large population-level genotype data sets to use as
controls. Where necessary, case/control samples were iteratively
matched to limit inflation in the test statistic due to platform or
cohort effects. Genome-wide imputation using the 1,000 Genomes
Project CEU sample as a reference panel resulted in a set of
approximately 86106 high-quality variants that were tested for
association with HIV-1 acquisition. We observed 11 variants that
passed the genome-wide significance threshold, all located in the
MHC region. Imputation and association testing of the CCR5D32
polymorphism demonstrated that this sample size and study design
are appropriate to detect strong associations that impact HIV-1
acquisition.
The fact that the top association in the full analysis (rs4418214)
is a tag SNP for HLA-B*57:01 and 27:05 highlights the frailty bias
inherent to studies of diseases with high mortality rates. HLA-B
alleles have been associated with reduced HIV-1 transmission in
heterosexual couples [21], likely due to the effects of HLA-B on
HIV-1 viral load, which decreases infectiousness. To further
explore the possibility that HLA-B alleles are also associated with
HIV-1 acquisition, we ran an analysis restricting the case
population to the 2,173 individuals with a known date of
seroconversion, assuming that cohorts of patients recruited soon
after HIV-1 acquisition are less likely to suffer from frailty bias.
This analysis resulted in an almost complete loss of signal at
rs4418214 that is unlikely to be due to the reduction in size of the
case population. Thus, the most parsimonious explanation for the
association result in the HLA class I region is that it reflects an
enrichment of alleles that protect against disease progression
(hence survival) rather than increasing acquisition.
Under ideal circumstances, this sample size provides approxi-
mately 80% power to detect a common variant (MAF=0.1) with
genotypic relative risk of 1.3 at genome-wide significance.
However, we recognize that the present study design allows for
a proportion of the sample to be misclassified (i.e. individuals at
average or low susceptibility to HIV-1 infection included as cases)
which can reduce power [22]. Nevertheless, even under assump-
tions including a large proportion of controls in the case group,
this sample size is suitable to discover large effect variants
(GRR.3, Figure S4 in Text S1). This is further evidenced by
our ability to detect the known effect of CCR5D32 homozygosity
on HIV-1 acquisition in this sample, even given imperfect
imputation.
Additionally, the lack of enrichment of the control population
for individuals with proven or suspected resistance against HIV-1
infection may also influence power [23]. However, in line with our
results, GWAS looking at HIV-1 acquisition in mother-to-child
transmission pairs [12], discordant couples [13], areas of
heightened prevalence [14] and in hemophiliacs exposed to
potentially contaminated blood products [16] (although much
smaller than the present study) have been similarly unable to
discover novel associations.
This large study population is useful for attempting to replicate
previous associations, particularly with genetic variants thought to
reduce HIV-1 acquisition, as they would be depleted in infected
individuals. None of the 22 previously reported variants tested in
this sample were associated with HIV-1 acquisition after
correcting for multiple tests. This lack of replication is consistent
with other, smaller GWAS of this phenotype [14]. These data
suggest that many or all of these variants do not appreciably
impact HIV-1 acquisition. Thus, evidence is mounting that
common polymorphisms affecting acquisition are either very
difficult to detect (perhaps due to weak effects) or absent, with the
exception of CCR5D32 homozygosity.
The early observation that CCR5D32 influences both acquisi-
tion (when homozygous) and disease progression (when heterozy-
gous) suggested shared biology between these phenotypes.
However, this proved not to be a generalizable observation since
variation at other loci, such as HLA class I and KIR, associate
with disease progression but are not generally believed to
modulate acquisition. Mechanisms mediating acquisition i.e.
permissiveness to HIV upon parenteral or mucosal exposure,
likely involve cellular targets and innate immune factors that play
none or a limited role in disease progression. On the other hand,
mediators of host tolerance (as defined by [24]) and of acquired
immunity are only expected to exert their effects after infection has
been established.
Although this study focuses on the host genetics of HIV-1
acquisition, it is possible that the extensive variation in HIV-1
genotype also plays a role in determining susceptibility. This
Figure 3. Analysis of bulk SNP effects shows no evidence for
enrichment of association signal across data sets. LD pruned SNP
sets falling below various p-value thresholds (grey shades, x-axis) were
selected based on association results calculated in five of six groups
(discovery set). Per individual scores were calculated in a non-
overlapping test set (Group 3) by summing the beta-weighted dosage
of all SNPs in that set. Model p-value (listed above bars) and variance
explained (using Nagelkerke’s pseudo R2, y-axis) were calculated by
regressing phenotype on per individual score using logistic regression.
doi:10.1371/journal.ppat.1003515.g003
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notion is supported by the observation that amino acid changes,
generally in response to host HLA pressure, result in decreased
viral fitness (reviewed in [25]). However, defining viral variants
that limit or enhance infection would require large-scale epidemi-
ological investigations in HIV-1 endemic areas.
Despite the large sample size and comprehensive genotype
information obtained through imputation, this study is still limited
to analysis of common variation with detectable effects present in
European samples. Thus, we cannot rule out whether multiple
common variants of small effect, population-specific variants or
rare variants exist that influence HIV-1 acquisition. Of particular
note, in light of the well-known effect of CCR5D32 on HIV
acquisition, is the inability to comprehensively test structural
variation using array-based genotyping platforms. Although SNPs
contained on commercial arrays have been shown to tag a large
proportion of common structural variants [26] it is still possible
that unobserved or poorly tagged structural variants contribute to
HIV acquisition. Detection of these types of effects will require
large-scale sequencing efforts, preferably in samples with known
levels of exposure to HIV-1.
Materials and Methods
Ethics statement
Ethical approval for this study was obtained from institutional
review boards at each of the Cohorts, Studies and Centers listed at
the end of the manuscript. All subjects provided written informed
consent.
Sample collection, genotyping and quality control
The International Collaboration for the Genomics of HIV was
established as a platform to combine all available genome-wide
SNP data sets obtained on HIV-1 infected individuals worldwide.
Patient material was collected at multiple clinical centers across
North America, Europe, Australia and Africa (a list of contributing
cohort studies and centers is given at the end of the paper).
Genotypes for uninfected control individuals were obtained
directly from three of the participating centers (GRIV, ACS,
CHAVI) and from the Illumina genotype control database (www.
illumina.com/icontroldb) and the Myocardial Infarction Genetics
Consortium (MIGen) (NIH NCBI dbGaP Study Accession:
phs000294.v1.p1) [18]. Each data set was subject to quality
control procedures performed prior to centralization of all data for
the combined analysis. However, to ensure consistency, all data
were subject to further quality control once submitted. Per data
set, samples with high missingness (,95% of sites successfully
genotyped) and high heterozygosity (inbreeding coefficient .0.1)
were removed. Ancestry was determined using EIGENSTRAT to
project sample data onto the HapMap III reference panel. For the
present analysis, only individuals clustering with the CEU/TSI
subset were retained. To remove samples genotyped by multiple
centers (and those with high relatedness) we performed identity-
by-state analysis taking the intersection of SNPs across all
genotyping platforms, using PLINK version 1.07 [27]. In the case
of duplicates, the sample contributing the larger number of
genotyped SNPs was retained. We further filtered out individuals
with relatedness higher than 0.125, adopting a strategy to
Table 1. Results for 22 SNPs previously reported to affect HIV-1 acquisition sorted by reported effect and genomic location.
SNP CHR BP (hg19) A1 A2
Frequency
HIV+
Frequency
HIV2 OR SE P Gene
Reported effect on
acquisition Reference
rs1800872 1 206946407 T G 0.245 0.232 1.08 0.030 0.01 IL10 Increased [34]
rs3732378 3 39307162 A G 0.163 0.164 0.97 0.035 0.35 CX3CR1 Increased [35]
rs3732379 3 39307256 T C 0.279 0.282 0.98 0.028 0.46 CX3CR1 Increased [35]
rs6850 7 44836314 G A 0.123 0.133 0.94 0.039 0.09 PPIA Increased [36]
rs754618 10 44886206 T C 0.311 0.304 1.01 0.028 0.73 CXCL12 Increased [37]
rs1946518 11 112035458 G T 0.590 0.592 0.98 0.026 0.49 IL18 Increased [38]
rs2280789 17 34207003 G A 0.136 0.134 1.04 0.038 0.30 CCL5 Increased [39]
rs2280788 17 34207405 C G 0.022 0.023 0.90 0.088 0.25 CCL5 Increased [39]
rs2107538 17 34207780 T C 0.183 0.180 1.02 0.034 0.49 CCL5 Increased [39]
rs2549782 5 96231000 T G 0.477 0.477 1.00 0.026 0.94 ERAP2 Decreased [40]
rs2070729 5 131819921 A C 0.428 0.426 1.02 0.026 0.50 IRF1 Decreased [41]
rs2070721 5 131825842 G T 0.427 0.426 1.02 0.026 0.50 IRF1 Decreased [41]
rs6996198 8 65463442 T C 0.159 0.167 0.97 0.035 0.46 CYP7B1 Decreased [42]
rs1552896 9 14841387 G C 0.227 0.227 1.01 0.032 0.77 FREM1 Decreased [15]
rs1801157 10 44868257 T C 0.200 0.209 0.97 0.032 0.36 CXCL12 Decreased [37]
rs10838525 11 5701001 T C 0.357 0.355 1.00 0.027 0.95 TRIM5 Decreased [43]
rs3740996 11 5701281 A G 0.113 0.117 0.93 0.040 0.05 TRIM5 Decreased [44]
rs1024611 17 32579788 G A 0.267 0.277 0.95 0.029 0.08 CCL2 Decreased [45]
rs1024610 17 32580231 T A 0.200 0.205 0.97 0.032 0.31 CCL2 Decreased [46]
rs2857657 17 32583132 G C 0.196 0.200 0.97 0.032 0.32 CCL2 Decreased [46]
rs4795895 17 32611446 A G 0.193 0.196 0.97 0.032 0.40 CCL11 Decreased [46]
rs1719134 17 34416946 A G 0.240 0.231 1.05 0.031 0.13 CCL3 Decreased [45]
Reported effects correspond to the A1 allele.
Frequency and odds ratio (OR) are calculated for the A1 allele with an OR.1 indicating a higher frequency of A1 in the HIV-1 infected sample.
doi:10.1371/journal.ppat.1003515.t001
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maximize sample retention. After sample removal, SNPs with high
missingness (.2%), low minor allele frequency (,1%) or that were
out of Hardy-Weinberg equilibrium (p,161026) were removed.
Case/control matching
To limit bias introduced due to the majority of the control
samples being genotyped separately from cases we used a 2-stage
case/control matching strategy. In the first round, cases and
controls were matched by platform and geographic origin. This
resulted in four clusters; The Netherlands (Illumina, Group 1),
France (Illumina, Group 2), North America and non-Dutch/non-
French European (Illumina, Groups 3 and 4), North America and
non-Dutch/non-French European (Affymetrix, Groups 5 and 6).
To test the success of this method at controlling inflation, we ran
association testing on all genotyped SNPs including the top PCs as
covariates per cluster and assessed lambda (Figure S1 in Text S1).
For samples ascertained from France and The Netherlands, this
was sufficient to control inflation in the test statistic (l,1, Figures
S1a–d in Text S1). For the remaining two clusters, we plotted each
sample based on their coordinates across the top two PCs and split
each cluster into two sub-clusters based on these coordinates. Sub-
clusters then underwent either 1:3 or 1:1 case/control matching
using Euclidean distance across the top 10 PCs (with the top PC
given twice the weight of the others). Samples were removed if no
suitable match could be identified. This strategy proved sufficient
to control inflation in these remaining clusters (Figures S1e–l in
Text S1).
Imputation and association testing
After sample matching and per group quality control, unob-
served SNP genotypes were imputed using the 1,000 Genomes
Project Phase I release integrated SNPs and indels (March 2012).
Two teams from this Collaboration performed the analysis
independently using different tools. The first team used BEAGLE
[28], the second team used the pipeline IMPUTE2, SNPTEST
and META [29,30] with a pre phasing step using ShaPEIT [31].
Per group, phenotype was regressed on genotype dosage including
population covariates calculated by EIGENSTRAT to control for
residual structure under both additive and recessive genetic
models. Association results were then combined using inverse-
variance weighted meta-analysis including a covariate to correct
for group-specific effects. The results obtained by each team were
compared for cross-validation and found to be highly consistent
(Figure S5 in Text S1). SNPs were considered associated if the
combined p-value was below the accepted level of genome-wide
significance (p,561028).
Polygenic analysis
We performed analysis to test for evidence of polygenic effects
using five of the six groups as a discovery set and Group 3 (the
largest single group) as the test set. To build a SNP set we first
filtered out all SNPs with low minor allele frequency (MAF,0.1)
and low imputation quality (R2,0.9) and removed the MHC
region. We then performed LD pruning informed by the p-value
calculated in the discovery set such that the SNP with the lowest p-
value was selected and all other SNPs in LD (r2.0.1) were
removed. The SNP with the lowest remaining p-value was then
selected and again all other SNPs in LD were removed. This
procedure was repeated until no remaining SNPs fell below the
selected PT. In the test set, per individual scores were generated by
summing the dosage of all SNPs in a set weighted by the effect size
(beta) calculated in the discovery set. We then regressed phenotype
on this score using logistic regression including top PCs. SNP set
pruning was performed using PLINK version 1.07 [27], logistic
regression, calculation of variance explained and results visualiza-
tion was performed using R version 2.12 (www.r-project.org) and
the Design package [32].
Testing previous associations
A list of SNPs previously reported to associate with HIV-1
acquisition was taken from Petrovski et al [14] and updated to
include recently reported associations. All SNPs were either
directly genotyped or imputed, and tested in the same logistic
regression/meta-analysis framework as all other variants.
Imputation and association testing of CCR5D32
CCR5D32 genotypes were obtained by individual cohorts using
either Sequenom genotyping, PCR or direct sequencing as
described in the original publications. Since genotype of this
deletion was not available in the control populations we used a
subset of the HIV+ sample with both genome-wide genotypes and
CCR5D32 types as a reference panel for imputation. For this, we
used the subset typed on the Illumina 1M platform (n= 1,100) to
maximize SNP coverage. Additionally, we included 383 non-
overlapping individuals with known CCR5D32 genotype from a
recent GWAS in hemophiliacs [16]. Phasing of the reference panel
and imputation was performed using ShaPEIT [31] and
IMPUTE2 [29,30]. We imputed CCR5D32 genotype in both
cases and controls using a leave-one-out strategy such that, if an
individual was present in both the reference and test sample, their
genotype information was removed from the reference panel and
imputation was carried out using the remaining samples as
reference. Association was tested under a recessive model and
assuming an additive or heterozygous advantage model.
Estimating power for variant detection
Power for variant detection was estimated over a wide range of
possible proportions of controls being misclassified as cases (Figure
S4 in Text S1). Calculations were made under an additive genetic
model assuming a risk variant of 10% frequency for a study of
6,300 cases and 7,200 controls at genome-wide significance
(p,561028). Calculations were performed using PAWE-3D
[22,33].
Cohorts, studies, and centers participating in the
International Collaboration for the Genomics of HIV
1. The AIDS clinical Trial Group (ACTG) in the USA
2. The AIDS Linked to the IntraVenous Experience (ALIVE)
Cohort in Baltimore, USA
3. The Amsterdam Cohort Studies on HIV infection and AIDS
(ACS) in the Netherlands
4. The ANRS CO18 in France
5. The ANRS PRIMO Cohort in France
6. The Center for HIV/AIDS Vaccine Immunology (CHAVI) in
the USA
7. The Danish HIV Cohort Study in Denmark
8. The Genetic and Immunological Studies of European and
African HIV-1+ Long Term Non-Progressors (GISHEAL)
Study, in France and Italy
9. The GRIV Cohort in France
10. The Hemophilia Growth and Development Study (HGDS)
in the USA
11. The Hospital Clinic-IDIBAPS Acute/Recent HIV-1 Infec-
tion cohort in Barcelona, Spain
12. The Icona Foundation Study in Italy
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13. The International HIV Controllers Study in Boston, USA
14. The IrsiCaixa Foundation Acute/Recent HIV-1 Infection
cohort in Barcelona, Spain
15. The Modena Cohort in Modena, Italy
16. The Multicenter AIDS Cohort Study (MACS), in Balti-
more, Chicago, Pittsburgh and Los Angeles, USA
17. The Multicenter Hemophilia Cohort Studies (MHCS)
18. The NCI Laboratory of Genomic Diversity in Frederick,
USA
19. The Pumwani Sex Workers Cohort in Nairobi, Kenya, and
Winnipeg, Canada
20. The San Francisco City Clinic Cohort (SFCCC) in San
Francisco, USA
21. The Sanger RCC Study in Oxford, UK, and in Uganda
22. The Swiss HIV Cohort Study (SHCS), in Switzerland
23. The US military HIV Natural History Study (NHS)
24. The Wellcome Trust Case Control Consortium (WTCCC3)
study of the genetics of host control of HIV-1 infection in
the Gambia
25. The West Australian HIV cohort Study
Supporting Information
Text S1 Includes Note S1: the cohorts and individuals
contributing to the International Consortium for the Genomics
of HIV, Tables S1, S2, S3, Figures S1, S2, S3, S4, S5 and
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